Key clinical point: Duvelisib is demonstrating activity and manageable toxicities among patients with relapsed/refractory peripheral T-cell lymphoma in an ongoing phase 2 trial.

Major finding: In the ongoing dose-expansion phase, the overall response rate is 52%, including a 36% complete response rate.

Study details: A report on the completed dose-optimization phase including 33 patients and the ongoing dose-expansion phase including 25 patients with relapsed/refractory peripheral T-cell lymphoma.

Disclosures: Support for the study came from Verastem Oncology and Secura Bio. Dr. Pro reported research funding from Verastem Oncology, Takeda, and other pharmaceutical companies and honoraria from Takeda and Seattle Genetics.